Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients-Reference-Cited by-同舟云学术

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Published:2017-12-28 Issue:6 Volume:24 Page:1337-1343
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Plenker Dennis,Bertrand Miriam,de Langen Adrianus J.,Riedel Richard,Lorenz Carina,Scheel Andreas H.,Müller Judith,Brägelmann Johannes,Daßler-Plenker Juliane,Kobe Carsten,Persigehl Thorsten,Kluge Alexander,Wurdinger Thomas,Schellen Pepijn,Hartmann Gunther,Zacherle Tobias,Menon Roopika,Thunnissen Erik,Büttner Reinhard,Griesinger Frank,Wolf Jürgen,Heukamp Lukas,Sos Martin L.,Heuckmann Johannes M.

Funder

North Rhine Westphalia/EFRE

Bundesministerium für Bildung und Forschung (BMBF)

Deutsche Krebshilfe (German Cancer Aid)

Deutsche Forschungsgemeinschaft (DFG)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA walk of specific fused oncogenes exhibit distinct fractal geometric characteristics in nucleotide patterns;2024-07-08

2. Joint DNA-RNA-based NGS for diagnosis and treatment of a rare CD47-MET fusion lung adenocarcinoma which was immunoresistant and savoltinib-sensitive: a case report;Frontiers in Immunology;2024-06-18

3. A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report;Translational Lung Cancer Research;2024-05

4. Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion;Frontiers in Oncology;2024-04-16

5. The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy;Pharmaceuticals;2024-03-30